Protara Therapeutics (NasdaqGM:TARA) Update / Briefing November 19, 2025 08:30 AM ET Company ParticipantsBill Conkling - Chief Commercial OfficerVishwesh Shah - Biotech Equity Research AssociateSoumit Roy - Managing Director and Head of Healthcare ResearchJesse Shefferman - Co-founder, Director, and CEOJackie Zummo - Co-founder and Chief Scientific Operations OfficerJesse Jones - Interventional NeuroradiologistJustine O'Malley - SVP of Investor Relations and Corporate AffairsConference Call ParticipantsLela ...

80% of patients that completed treatment and 100% of patients that completed the eight-week response assessment achieved clinical successClinical success achieved with one or two doses of TARA-002 in 88% of patients TARA-002 demonstrated favorable safety and tolerability profile with no serious adverse events reportedCompany to host conference call and webcast featuring Key Opinion Leader Dr. Jesse Jones at 8:30 a.m. ET NEW YORK, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a ...